Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 2Sarcoma 1Other hematologic neoplasm 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Blood Specimen Collection 35Methods 25Early Intervention, Educational 24Standard of Care 21Colposcopy 21Surveys and Questionnaires 19Educational Status 18Sentinel Lymph Node Biopsy 17Cisplatin 17Counseling 16Brachytherapy 16Exercise 15Interviews as Topic 13Carboplatin 13Therapeutics 12Surgical Procedures, Operative 11Paclitaxel 11Magnetic Resonance Spectroscopy 11Indocyanine Green 11Biopsy 11Radiotherapy 10Practice Guidelines as Topic 10Palliative Care 10Human Papillomavirus DNA Tests 10Behavior Therapy 10Specimen Handling 9Radiotherapy, Intensity-Modulated 9Psychiatric Rehabilitation 9Lymph Node Excision 9Genetic Testing 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Darbepoetin alfa × Gynecologic × Clear all
NCT06184867 2026-03-06

CATALYST

Rutgers, The State University of New Jersey

Phase NA Completed
50 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡